Literature DB >> 19733449

Working memory deficits predict short-term smoking resumption following brief abstinence.

Freda Patterson1, Christopher Jepson, James Loughead, Kenneth Perkins, Andrew A Strasser, Steven Siegel, Joseph Frey, Ruben Gur, Caryn Lerman.   

Abstract

As many as one-half of smokers relapse in the first week following a quit attempt, and subjective reports of cognitive deficits in early abstinence are associated with increased relapse risk. This study examined whether objective cognitive performance after 3 days of abstinence predicts smoking resumption in a 7-day simulated quit attempt. Sixty-seven treatment-seeking smokers received either varenicline or placebo (randomized double-blind) for 21 days. Following medication run-up (days 1-10), there was a 3-day mandatory (biochemically confirmed) abstinence period (days 11-13) during which working memory (Letter-N-Back Task) and sustained attention (Continuous Performance Task) were assessed (day 13). Participants were then exposed to a scheduled smoking lapse and instructed to try to remain abstinent for the next 7 days (days 15-21). Poorer cognitive performance (slower correct reaction time on Letter-N-Back task) during abstinence predicted more rapid smoking resumption among those receiving placebo (p=0.038) but not among those receiving varenicline. These data lend further support for the growing recognition that cognitive deficits involving working memory are a core symptom of nicotine withdrawal and a potential target for the development of pharmacological and behavioral treatments. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19733449      PMCID: PMC2815089          DOI: 10.1016/j.drugalcdep.2009.07.020

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  17 in total

1.  Working memory in cigarette smokers: comparison to non-smokers and effects of abstinence.

Authors:  Adrianna Mendrek; John Monterosso; Sara L Simon; Murray Jarvik; Arthur Brody; Richard Olmstead; Catherine P Domier; Mark S Cohen; Monique Ernst; Edythe D London
Journal:  Addict Behav       Date:  2005-07-11       Impact factor: 3.913

Review 2.  Effects of abstinence from tobacco: valid symptoms and time course.

Authors:  John R Hughes
Journal:  Nicotine Tob Res       Date:  2007-03       Impact factor: 4.244

Review 3.  Translational research in medication development for nicotine dependence.

Authors:  Caryn Lerman; Mark G LeSage; Kenneth A Perkins; Stephanie S O'Malley; Steven J Siegel; Neal L Benowitz; William A Corrigall
Journal:  Nat Rev Drug Discov       Date:  2007-09       Impact factor: 84.694

4.  Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice.

Authors:  Jennifer A Davis; John R James; Steven J Siegel; Thomas J Gould
Journal:  J Neurosci       Date:  2005-09-21       Impact factor: 6.167

5.  Increases in hyperactive-impulsive symptoms predict relapse among smokers in nicotine replacement therapy.

Authors:  Margaret Rukstalis; Christopher Jepson; Freda Patterson; Caryn Lerman
Journal:  J Subst Abuse Treat       Date:  2005-06

6.  Comparison of the continuous performance test with and without working memory demands in healthy controls and patients with schizophrenia.

Authors:  M M Kurtz; J D Ragland; W Bilker; R C Gur; R E Gur
Journal:  Schizophr Res       Date:  2001-03-30       Impact factor: 4.939

7.  Baseline reaction time predicts 12-month smoking cessation outcome in formerly depressed smokers.

Authors:  Jon D Kassel; Marisa Yates; Richard A Brown
Journal:  Psychol Addict Behav       Date:  2007-09

8.  Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice.

Authors:  Jonathan D Raybuck; George S Portugal; Caryn Lerman; Thomas J Gould
Journal:  Behav Neurosci       Date:  2008-10       Impact factor: 1.912

9.  Varenicline improves mood and cognition during smoking abstinence.

Authors:  Freda Patterson; Christopher Jepson; Andrew A Strasser; James Loughead; Kenneth A Perkins; Ruben C Gur; Joseph M Frey; Steven Siegel; Caryn Lerman
Journal:  Biol Psychiatry       Date:  2008-10-08       Impact factor: 13.382

10.  Dose-related enhancement of mood and cognition in smokers administered nicotine nasal spray.

Authors:  Carol S Myers; Richard C Taylor; Eric T Moolchan; Stephen J Heishman
Journal:  Neuropsychopharmacology       Date:  2007-04-18       Impact factor: 7.853

View more
  102 in total

1.  Chronic fluoxetine ameliorates adolescent chronic nicotine exposure-induced long-term adult deficits in trace conditioning.

Authors:  David A Connor; Thomas J Gould
Journal:  Neuropharmacology       Date:  2017-08-02       Impact factor: 5.250

2.  Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats.

Authors:  Thomas J Hopkins; Laura E Rupprecht; Matthew R Hayes; Julie A Blendy; Heath D Schmidt
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

Review 3.  Pharmacological enhancement of drug cue extinction learning: translational challenges.

Authors:  K M Kantak; B Á Nic Dhonnchadha
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

4.  The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice.

Authors:  Derek S Wilkinson; Thomas J Gould
Journal:  Behav Brain Res       Date:  2011-04-14       Impact factor: 3.332

5.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

Review 6.  Are executive function and impulsivity antipodes? A conceptual reconstruction with special reference to addiction.

Authors:  Warren K Bickel; David P Jarmolowicz; E Terry Mueller; Kirstin M Gatchalian; Samuel M McClure
Journal:  Psychopharmacology (Berl)       Date:  2012-03-24       Impact factor: 4.530

Review 7.  Cognitive enhancement as a treatment for drug addictions.

Authors:  Mehmet Sofuoglu; Elise E DeVito; Andrew J Waters; Kathleen M Carroll
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

8.  Chronic smoking, but not acute nicotine administration, modulates neural correlates of working memory.

Authors:  Matthew T Sutherland; Thomas J Ross; Diaá M Shakleya; Marilyn A Huestis; Elliot A Stein
Journal:  Psychopharmacology (Berl)       Date:  2010-09-23       Impact factor: 4.530

Review 9.  Mouse models for studying genetic influences on factors determining smoking cessation success in humans.

Authors:  F Scott Hall; Athina Markou; Edward D Levin; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

10.  Implicit attitudes towards smoking predict long-term relapse in abstinent smokers.

Authors:  Adriaan Spruyt; Valentine Lemaigre; Bihiyga Salhi; Dinska Van Gucht; Helen Tibboel; Bram Van Bockstaele; Jan De Houwer; Jan Van Meerbeeck; Kristiaan Nackaerts
Journal:  Psychopharmacology (Berl)       Date:  2015-03-13       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.